References
- Ensuring value for money in health care: the role of health technology assessment in the European Union. Observatory Studies Series No. 11. Geneva Switzerland: World Health Organization, on behalf of European Observatory for Health Systems and Policies; 2008.
- Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J. 2009;15(5):395–400.
- Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–440.
- Kim C, Prasad V. Strength of validation for surrogate end points used in the US food and drug administration’s approval of oncology drugs. Mayo Clin Proc. 2016. DOI:10.1016/j.mayocp.2016.02.012
- Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–613.
- European Network for Health Technology Assesment. Endpoints used in relative effectiveness assessment: surrogate endpoints. [cited 2022 Feb 17]. Available from: https://www.eunethta.eu/wp-content/uploads/2018/01/Endpoints-used-in-Relative-Effectiveness-Assessment-Surrogate-Endpoints_Amended-JA1-Guideline_Final-Nov-2015.pdf
- Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21(1):7–12.
- Davis S, Tappenden P, Cantrell A. A review of studies examining the relationship between Progression-Free survival and overall survival in advanced or metastatic cancer [internet]. London: National Institute for Health and Care Excellence (NICE); 2012.
- Bikdeli B, Punnanithinont N, Akram Y, et al. Two decades of cardiovascular trials with primary surrogate endpoints: 1990–2011. JAHA. 2017;6(3):e005285.
- Fiteni F, Westeel V, Pivot X, et al. Endpoints in cancer clinical trials. J Visc Surg. 2014;151(1):17–22.
- Smith N, Fu AC, Fisher T, et al. Oncology drugs and added benefit: insights from 3 european health technology assessment agencies on the role of efficacy endpoints. J Med Econ. 2022;25(1):1–6.
- Ciani O, Grigore B, Blommestein H, et al. Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies. Med Decis Making. 2021;41(4):439–452.
- Surrogate endpoint resources for drug and biologic development. US Food & Drug Administration; 2022. [cited 2022 Jan 27]. Available from: https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
- Petrou P. Assessing the pricing and benefits of oncology products: an update. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):335–342.